Alex Aravanis is the CEO and co-founder of Moonwalk Biosciences, a biotechnology company pioneering precision epigenetic medicines. In this episode, Chris and Alex discuss Moonwalk’s innovative approach to developing a new class of medicines aimed at treating complex diseases and potentially extending human healthspan.
The Finer Details:
The concept of epigenetics as the “source code” for cell states
Moonwalk’s technology for analyzing and modifying the epigenome
The company’s focus on cardiometabolic diseases and adiposity
Comparison of Moonwalk’s approach to other epigenetic reprogramming strategies
Potential applications in treating obesity and metabolic disorders
The use of AI and machine learning in epigenetic research
Future directions and challenges for Moonwalk Biosciences
If you use Apple Podcast (the player app) you will see a transcript. I was not able to copy the text however because…that functionality is blocked to serve Apple’s economic interests.
